Munich, Germany- Biopharma professionals facing challenges in the current market are invited to attend BioPharma Deals: The Survival Series, a two-day strategic conference designed to provide real-world solutions and insights. The conference will take place on November 24-25, 2025 in Munich, Germany.
In light of the tightening capital markets, evolving regulatory landscapes, and strategic dealmaking, this focused event aims to guide business development, licensing, and investment leaders in the biopharma industry. Attendees can expect to gain insider perspectives from experienced executives, investors, and legal experts on navigating the current environment and forging new paths forward.
The conference will feature opening keynotes and CEO insights from industry leaders, providing strategic perspectives on the dynamic dealmaking landscape. Attendees will also have the opportunity to explore real-life transactions and hear candid insights on licensing, mergers and acquisitions, and collaborative deal models through case studies and expert panel sessions.
In addition, hands-on workshops and practical frameworks will be offered to sharpen attendees’ approach to deal structuring, term sheet design, valuation methodology, and investor engagement. The conference will also provide various networking opportunities, including roundtables and one-on-one partnering, allowing attendees to engage directly with key stakeholders from the biotech, pharma, and investment communities.
“Whether you’re seeking capital, sourcing innovation, or recalibrating your growth strategy, BioPharma Deals: The Survival Series offers a rare opportunity to reset and realign in an uncertain market,” said conference spokesperson Kelly Rose.
Interested attendees can register for the conference at https://biopharmadeals.com/registration.html.
For media inquiries, speaking opportunities, or partnership requests, please contact Kelly Rose at kelly@biopharmadeals.com.
This event is distributed by https://pressat.co.uk/ and promises to provide valuable insights and solutions to the most pressing dealmaking and funding challenges faced by biotech and pharma companies today. Don’t miss this opportunity to gain strategic perspectives, network with industry leaders, and sharpen your approach to dealmaking in the biopharma industry.
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.